Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMVT NASDAQ:KYMR NASDAQ:PCVX NASDAQ:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMVTImmunovant$31.11-4.8%$28.50$14.32▼$36.28$6.71B0.762.56 million shs864,698 shsKYMRKymera Therapeutics$74.13-0.6%$83.01$36.65▼$103.00$6.14B2.02494,538 shs639,437 shsPCVXVaxcyte$47.36-2.9%$55.20$29.08▼$65.00$7.04B1.241.47 million shs1.11 million shsZYMEZymeworks$24.04-4.2%$25.88$11.51▼$29.75$1.83B1.15738,486 shs464,841 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMVTImmunovant+4.88%-2.48%+17.35%+22.54%+112.97%KYMRKymera Therapeutics+1.96%-8.41%-9.79%-10.64%+68.57%PCVXVaxcyte+3.90%-4.50%-12.30%-17.76%+44.09%ZYMEZymeworks+3.08%-1.49%-5.92%+4.24%+2,509,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMVTImmunovant$31.11-4.8%$28.50$14.32▼$36.28$6.71B0.762.56 million shs864,698 shsKYMRKymera Therapeutics$74.13-0.6%$83.01$36.65▼$103.00$6.14B2.02494,538 shs639,437 shsPCVXVaxcyte$47.36-2.9%$55.20$29.08▼$65.00$7.04B1.241.47 million shs1.11 million shsZYMEZymeworks$24.04-4.2%$25.88$11.51▼$29.75$1.83B1.15738,486 shs464,841 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMVTImmunovant+4.88%-2.48%+17.35%+22.54%+112.97%KYMRKymera Therapeutics+1.96%-8.41%-9.79%-10.64%+68.57%PCVXVaxcyte+3.90%-4.50%-12.30%-17.76%+44.09%ZYMEZymeworks+3.08%-1.49%-5.92%+4.24%+2,509,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMVTImmunovant 2.45Hold$37.3320.00% UpsideKYMRKymera Therapeutics 2.95Moderate Buy$118.1059.31% UpsidePCVXVaxcyte 2.63Moderate Buy$86.0081.59% UpsideZYMEZymeworks 2.91Moderate Buy$38.0058.07% UpsideCurrent Analyst Ratings BreakdownLatest ZYME, PCVX, IMVT, and KYMR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026ZYMEZymeworks HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$46.005/26/2026IMVTImmunovant GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$44.00 ➝ $62.005/22/2026IMVTImmunovant Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$23.00 ➝ $30.005/21/2026IMVTImmunovant CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/21/2026IMVTImmunovant HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $40.005/21/2026IMVTImmunovant Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $43.005/8/2026ZYMEZymeworks Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$33.00 ➝ $34.005/6/2026KYMRKymera Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$106.004/30/2026KYMRKymera Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$119.004/27/2026ZYMEZymeworks Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026KYMRKymera Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMVTImmunovantN/AN/AN/AN/A$4.19 per shareN/AKYMRKymera Therapeutics$39.21M155.52N/AN/A$19.42 per share3.82PCVXVaxcyteN/AN/AN/AN/A$20.51 per shareN/AZYMEZymeworks$105.96M16.57N/AN/A$3.59 per share6.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMVTImmunovant-$505.61M-$2.78N/AN/AN/AN/A-65.66%-59.88%8/10/2026 (Estimated)KYMRKymera Therapeutics-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%8/10/2026 (Estimated)PCVXVaxcyte-$766.63M-$6.88N/AN/AN/AN/A-32.51%-29.51%8/5/2026 (Estimated)ZYMEZymeworks-$81.13M-$1.37N/AN/AN/A-126.92%-37.97%-25.31%8/6/2026 (Estimated)Latest ZYME, PCVX, IMVT, and KYMR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q4 2026IMVTImmunovant-$0.60-$0.73-$0.13-$0.73N/AN/A5/7/2026Q1 2026ZYMEZymeworks-$0.10-$0.59-$0.49-$0.59$24.38 million$2.41 million5/6/2026Q1 2026PCVXVaxcyte-$1.7411-$2.30-$0.5589-$2.30$12.50 millionN/A4/30/2026Q1 2026KYMRKymera Therapeutics-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 million3/31/2026Q4 2025ZYMEZymeworksN/A-$0.59N/A-$0.59N/A$2.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIMVTImmunovantN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMVTImmunovantN/A9.099.09KYMRKymera TherapeuticsN/A10.8110.81PCVXVaxcyteN/A7.497.49ZYMEZymeworksN/A10.8210.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMVTImmunovant47.08%KYMRKymera TherapeuticsN/APCVXVaxcyte96.78%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipIMVTImmunovant1.80%KYMRKymera Therapeutics15.98%PCVXVaxcyte3.30%ZYMEZymeworks33.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMVTImmunovant120205.31 million201.61 millionOptionableKYMRKymera Therapeutics17082.26 million69.11 millionOptionablePCVXVaxcyte160144.40 million139.63 millionOptionableZYMEZymeworks46073.02 million48.55 millionN/AZYME, PCVX, IMVT, and KYMR HeadlinesRecent News About These CompaniesZymeworks (ZYME) Gets a Buy from Wells FargoJune 3 at 1:53 PM | theglobeandmail.comAnalyzing PyroGenesis Canada (NASDAQ:PYRGF) & Zymeworks (NASDAQ:ZYME)May 31, 2026 | americanbankingnews.comZymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC OptionalityMay 22, 2026 | seekingalpha.comVanguard Group Inc. Increases Position in Zymeworks Inc. $ZYMEMay 15, 2026 | marketbeat.comZymeworks Authorizes 2026 Share Repurchase Program, Affirms LiquidityMay 14, 2026 | tipranks.comZymeworks’ Earnings Call Balances Progress And PressureMay 14, 2026 | theglobeandmail.comZymeworks Announces Share Repurchase Program of up to $125 Million of its Common StockMay 14, 2026 | financialpost.comFZymeworks Announces Share Repurchase Program of up to $125 Million of its Common StockMay 14, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Zymeworks (ZYME) and Insmed (INSM)May 14, 2026 | theglobeandmail.comZymeworks Announces Participation in Upcoming Investor ConferencesMay 13, 2026 | financialpost.comFZymeworks Announces Participation in Upcoming Investor ConferencesMay 13, 2026 | globenewswire.comZymeworks Inc. 2026 Q1 - Results - Earnings Call PresentationMay 12, 2026 | seekingalpha.comHere's What Analysts Are Forecasting For Zymeworks Inc. (NASDAQ:ZYME) After Its First-Quarter ResultsMay 11, 2026 | finance.yahoo.comA Look At Zymeworks (ZYME) Valuation After Earnings Miss And Key FDA And Capital Return UpdatesMay 9, 2026 | finance.yahoo.comZymeworks Q1 Earnings Call HighlightsMay 9, 2026 | marketbeat.comZymeworks Inc. (ZYME) Q1 2026 Earnings Call TranscriptMay 9, 2026 | seekingalpha.comZymeworks (NASDAQ:ZYME) Trading Down 8.9% After Earnings MissMay 8, 2026 | marketbeat.comWells Fargo & Company Forecasts Strong Price Appreciation for Zymeworks (NASDAQ:ZYME) StockMay 8, 2026 | marketbeat.comZymeworks (ZYME) Q1 2026 Earnings TranscriptMay 8, 2026 | finance.yahoo.comZymeworks (NASDAQ:ZYME) Posts Quarterly Earnings Results, Misses Estimates By $0.49 EPSMay 7, 2026 | marketbeat.comZymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue EstimatesMay 7, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZYME, PCVX, IMVT, and KYMR Company DescriptionsImmunovant NASDAQ:IMVT$31.11 -1.56 (-4.78%) Closing price 04:00 PM EasternExtended Trading$30.58 -0.53 (-1.69%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Kymera Therapeutics NASDAQ:KYMR$74.13 -0.48 (-0.64%) Closing price 04:00 PM EasternExtended Trading$74.16 +0.03 (+0.03%) As of 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Vaxcyte NASDAQ:PCVX$47.36 -1.40 (-2.87%) Closing price 04:00 PM EasternExtended Trading$47.35 -0.01 (-0.02%) As of 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Zymeworks NASDAQ:ZYME$24.04 -1.06 (-4.22%) Closing price 04:00 PM EasternExtended Trading$23.16 -0.88 (-3.64%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
